Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies
- Denis Malvy†1, 2, 3,
- Khaled Ezzedine†1, 2, 3Email author,
- Maria Mamani-Matsuda3,
- Brigitte Autran4,
- Hugues Tolou5,
- Marie-Catherine Receveur1, 2,
- Thierry Pistone1, 2,
- Jérome Rambert3,
- Daniel Moynet3 and
- Djavad Mossalayi1, 2
© Malvy et al; licensee BioMed Central Ltd. 2009
Received: 21 June 2009
Accepted: 10 December 2009
Published: 10 December 2009
Chikungunya fever is an emerging arboviral disease characterized by an algo-eruptive syndrome, inflammatory polyarthralgias, or tenosynovitis that can last for months to years. Up to now, the pathophysiology of the chronic stage is poorly understood.
We report the first case of CHIKV infection with chronic associated rheumatism in a patient who developed progressive erosive arthritis with expression of inflammatory mediators and persistence of specific IgM antibodies over 24 months following infection.
Understanding the specific features of chikungunya virus as well as how the virus interacts with its host are essential for the prevention, treatment or cure of chikungunya disease.
Chikungunya virus (CHIKV) is an enveloped positive-strand RNA alphavirus which can infect human epithelial and endothelial cells, fibroblasts or macrophages [1, 2]. A CHIKV epidemic recently occurred on islands of the Indian Ocean in 2005 [3–5]. CHIKV infection may cause an algoeruptive syndrome with disabling joint pain and recurrent rheumatic manifestations [6–8]. Until now, it has been assumed that complete recovery occurs, even when symptoms are long lasting. Remarkably, despite the severity and duration of arthritis, articular destruction has been reported very rarely . We report the case of a patient with CHIKV infection presenting with severe chronic rheumatism accompanied by progressive destructive arthritis and dysregulated expression of inflammatory mediators.
In November 2005, a 60-year-old French man living in La Réunion experienced an acute influenza-like illness with diffuse arthralgia affecting bilaterally the distal inter-phalangeal joints of the fingers and the toes with hand tenosynovitis. His past medical history was unremarkable with no family history of inflammatory rheumatism.
Serology demonstrated the presence of anti-CHIKV IgM and confirmed the diagnosis of CHIKV infection. During the following months, the patient had persisting inflammatory arthralgia and joint stiffness which were not improved by symptomatic treatment. One year later, he developed refractory tenosynovitis in the wrists.
On February 15, 2007, the patient returned to France and consulted in our department. He complained of persistent symmetrical inflammatory arthritis of the wrists with fixed oedema of the two hands predominating on the right. Hand synovitis of the extensors and the flexors of wrists and fingers were noted. Lymphocyte immunophenotyping showed an increased CD4 T-cell count at 1,18 × 109/L (63.5%) and an activated CD45/CD3 (-) T-cell count at 0.209 × 109/L (11.3%), and CD45/CD3 (+) at 0,119 × 109/L (6.4%). Serum immunoglobulin was normal, as were the C3 and C4 complement fractions. No markers of autoimmunity were found, notably anti-citrullin peptide antibodies, antinuclear antibodies or cryoglobulinemia. The HLA B27 gene was positive and HLA system class II genotyping revealed an HLA-DRB1.03.11 genotype.
T cell function was assessed using proliferation assays and ELISPOT quantification of interferon-γ (IFN-γ) production by T cells. No proliferative response or IFN-γ production could be detected in response to CHIKV antigens derived from an in-house preparation of β-propionolactone-inactivated virus (French Armed Forces Institute of Tropical Medicine, Marseilles, France). T cell viability was ascertained by concurrent detection in the same assays of T cells responding to candidin and herpes simplex virus-1 antigens tested as controls.
Peripheral blood lymphocytes (PBL) from the patient and from three healthy control individuals were isolated and analysed at a transcriptomic level using real-time reverse transcriptase-polymerase chain reaction (PCR) to detect mRNA species encoding inflammatory mediators (RT2 Profiler™ PCR Array Human Inflammatory Cytokine and Receptors, SuperArray, Frederick, USA). Each PCR used the same quantity of total RNA from each cell culture and the absence of a signal after 35 PCR cycles was taken as the threshold for the mRNA not being detectable. These PCR analyses were completed by measurement of cytokine levels in the serum and in the 48 h PBL-derived supernatant. These analyses were performed on samples obtained before treatment initiation and at the four-month follow-up.
Gene expression profile in a patient with chikungunya virus infection before and four months following methotrexate (MTX) treatment.
Before MTX Fold/Control
After MTX Fold/Control
Before/after Fold ††
Tumor necrosis factor-α (TNFsuperfamily, member 2)
Lymphotoxin alpha (TNF superfamily, member 1)
C-reactive protein, pentraxin-related
Interleukin 1, alpha
Interleukin 1 family, member 5 (delta)
Interleukin 1 family, member 6 (epsilon)
Interleukin 1 family, member 7 (zeta)
Interleukin 1 family, member 8 (eta)
Interleukin 1 family, member 9
Interleukin 1 receptor antagonist
Interleukin 9 receptor
Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)
Complement component 3
CD40 ligand (TNF superfamily, hyper-IgM syndrome)
Inflammatory chemokines and their receptors
Chemokine (C motif) receptor 1
Chemokine (C-C motif) ligand 1
Chemokine (C-C motif) ligand 7
Chemokine (C-C motif) ligand 8
Chemokine (C-C motif) ligand 16
Chemokine (C-C motif) ligand 24
Chemokine (C-C motif) ligand 26
Chemokine (C-C motif) receptor 2
Chemokine (C-C motif) receptor 6
Chemokine (C-C motif) receptor 8
Chemokine (C-C motif) receptor 9
Chemokine (C-X-C motif) ligand 2
Chemokine (C-X-C motif) ligand 5
Chemokine (C-X-C motif) ligand 14
Cytokine profiles from patient peripheral blood mononuclear cell supernatants before and four months following methotrexate (MTX) treatment.
Four months following initiation of treatment, the expression of most of the above mRNAs was attenuated, and expression of CD40L, IFN-α and IL-22 remained undetectable. At this time, cytokine levels measured in the cell culture supernatant were markedly decreased and surface CD40L expression on peripheral blood cells could not be detected (data not shown).
Chikungunya virus infection is usually a self-limiting disease characterized by arthralgia with late peripheral joint pain in the smaller joints [11, 12]. A sole case of late articular destruction after decades of post CHIKV-chronic rheumatism has been reported with a questionable relationship to the CHIKV infection . Our case is remarkable for the clearly erosive arthritis pattern accompanied with enthesopathies, which developed within less than two years of the index CHIKV infection .
The patient was positive for HLA B27 antigen although no clinical rheumatologic manifestations had been noted before the CHIKV infection. For this reason, we can conclude that he developed a form of spondylarthropathy. Concerning the acute phase, recent findings suggested that both classical and severe symptoms of chikungunya disease closely reflect CHIKV tissue tropism , with fibroblasts being the primary targets, as they are for other alphaviruses [1, 15]. The molecular basis of this tropism may combine specific interactions between virus and host cells and tissues, and an intrinsic lower ability of this cell type to control CHIKV infection [8, 14].
The pathogenesis of persistent arthritis remains unclear although persistent infection of synovial macrophages has been documented for other alphaviruses [16, 17]. Moreover, factors secreted by infected macrophages seem to play a pivotal role in joint inflammation . To date, the presence of CHIKV RNA in joints during the acute phase of infection has only been demonstrated in animal models [14, 19]. CHIKV RNA has never been detected in joint tissues during the late phase, although it has been found in human muscle satellite cells three months after infection . Taken together with reports of the presence of long lasting IgM anti-CHIKV antibodies , these findings could indicate the persistence of CHIKV in certain host tissues or cells. However, there is no evidence that viral persistence is necessary to sustain chronic joint pathology after the infection. In our case, an antigen-specific immunopathology may underlie the development of chronic joint disease due to the presentation of specific autologous or microbial arthritogenic peptides . This would be consistent with the notion of an infectious trigger for immune activation derived from molecular mimicry which has been postulated as a potential pathogenic mechanism in autoimmunity [22–24].
High levels of pro-inflammatory cytokines IL-1, IL-6 and IL-8 were detected in cell supernatants from the patient's lymphocytes and elevated expression of genes encoding a variety of cytokines and chemokines known to be implicated in the pathogenesis of arthritis were also observed [25, 26]. In contrast, IFN-α, IL-4 and IL-5 were not detected in cell supernatants whereas IL-10 was increased. Of interest, the lymphocytes failed to express genes encoding IFN-α, IL-22 and CD40L, which are required for B cell differentiation, optimal immunoglobulin isotype switching and antiviral activity. Although the persistence of specific IgM antibodies has been documented after CHIKV infections , an association between these antibodies and disease severity has not been established. It is possible that antibody persistence may be determined by the persistence of virus in host tissues since, in acute arboviral infections, IgM are generally no longer detectable after 6-12 months. Unfortunately, in our case, it was not possible to perform RT-PCR for detection of CHIKV in synovial fluid or tissue
Viruses have evolved a number of mechanisms for suppressing host immune responses. In particular, viral proteins may suppress the retinoic acid-inducible gene I-like helicase and Toll-like receptor pathways important for the expression of type 1-IFNs, such as IFN-α isoforms, which play a crucial role in eliminating viral infections [14, 27–29]. Immunoglobulin class switching from IgM to IgG and IgA is central to immunity against viruses and requires the activation of B-cells by T-cells via cytokine interactions with CD154/CD40L. Mutations in the CD40L gene have been observed in cases of inherited hyper-IgM X-linked immunodeficiences . In this context, CHIKV may be able to evade T-cell dependent IgG and IgA responses by attenuating CD40L gene expression. Such a mechanism has been postulated previously to explain hyper IgM syndrome associated with various viral infections [30–32].
We report here a case of CHIKV infection with joint and bone erosion and persistent specific IgM nearly two years following infection. Transcriptomic and protein analysis revealed individual genes which could be implicated in the pathogenesis of chronic arthritis; these genes have not been associated previously with alphavirus-induced arthritis.
The patient has provided written consent to the use of his history for publication
- Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, et al: Characterisation of reemerging Chikungunya virus. PLoS Pathog. 2007, 3: e89-10.1371/journal.ppat.0030089.View ArticlePubMedPubMed CentralGoogle Scholar
- Ozden S, Huerre M, Riviere JP, Coffey LL, Afonso PV, Mouly V, et al: Human muscle satellite cells as targets of Chikungunya virus. PLoS ONE. 2007, 6: e527-10.1371/journal.pone.0000527.View ArticleGoogle Scholar
- Mason PJ, Haddow AJ: An epidemic of virus disease in southern province, Tanganyika territory in 53; an additional note on chikungunya virus isolations and serum antibodies. Trans R Soc Trop Med Hyg. 1952, 51: 238-40. 10.1016/0035-9203(57)90022-6.View ArticleGoogle Scholar
- Enserink M: Infectious diseases. Massive outbreak draws fresh attention to little known virus. Science. 2006, 311: 1085-10.1126/science.311.5764.1085a.View ArticlePubMedGoogle Scholar
- Gratz NG: Emerging and resurging vector-borne diseases. Ann Rev Entomol. 1999, 44: 51-75. 10.1146/annurev.ento.44.1.51.View ArticleGoogle Scholar
- Sissoko D, Moendandze A, Malvy D, Giry C, Ezzedine K, Solet J-L, Pierre V: Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005-2006: a population-based survey. PLoS ONE. 2008, 3: e3066-10.1371/journal.pone.0003066.View ArticlePubMedPubMed CentralGoogle Scholar
- Sissoko D, Malvy D, Ezzedine K, Renault P, Moscetti F, Ledrans M, Pierre V: Post-Epidemic Chikungunya Disease on Reunion Island: Course of Rheumatic Manifestations and Associated Factors over a 15-Month Period. PLoS Neglect Trop Dis. 2009, 3: e389-10.1371/journal.pntd.0000389.View ArticleGoogle Scholar
- Lokireddy S, Vemula S, Vadde R: Connective tissue metabolism in Chikungunya patients. Virol J. 2008, 5: 31-10.1186/1743-422X-5-31.View ArticlePubMedPubMed CentralGoogle Scholar
- Brighton SW, Simson IW: A destructive arthropathy following chikungunya virus arthritis - a possible association. Clin Rheumatol. 1984, 3: 253-8. 10.1007/BF02030766.View ArticlePubMedGoogle Scholar
- Pastorino B, Bessaud M, Grandadam M, Murri S, Tolou HJ, Peyrefitte CN: Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African chikungunya viruses. J Virol Methods. 2005, 124: 65-71. 10.1016/j.jviromet.2004.11.002.View ArticlePubMedGoogle Scholar
- Fourie ED, Morrison JG: Rheumatoid arthritic syndrome after chikungunya fever. S Afr Med J. 1979, 56: 130-2.PubMedGoogle Scholar
- Kennedy AC, Fleming J, Solomon L: Chikungunya viral arthropathy: a clinical description. J Rheumatol. 1980, 7: 231-6.PubMedGoogle Scholar
- Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, Hance P, Kraemer P, Ali Mohamed A, de Lamballerie X, Charrel R, Tolou H: Chikungunya infection. An emerging rheumatism among travellers returned from the Indian Ocean Islands. Medicine. 2007, 86: 123-37. 10.1097/MD/0b013e31806010a5.View ArticlePubMedGoogle Scholar
- Couderc T, Chrétien F, Schilte C, Disson O, Madly B, Benhassine-Guivel F, Touret Y, Barau G, Cayet N, Schuffenecker I, Desprès P, Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M: A mouse model for chikungunya: young age and inefficient type-1 interferon signaling are risk factors for severe disease. PLoS Pathog. 2008, 4: e29-10.1371/journal.ppat.0040029.View ArticlePubMedPubMed CentralGoogle Scholar
- Ryman KD, Klimstra WB, Nguyen KB, Biron CA, Johnston RE: Alpha/beta interferon protects adult mice from fatal Sindbies virus infection and is an important determinant of cell and tissue tropism. J Virol. 2000, 74: 3066-78. 10.1128/JVI.74.7.3366-3378.2000.View ArticleGoogle Scholar
- Suhrbier A, La Linn M: Clinical and pathologic aspects of arthritis due to Ross River and other alphaviruses. Curr Opin Rheumatol. 2004, 16: 374-9. 10.1097/01.bor.0000130537.76808.26.View ArticlePubMedGoogle Scholar
- Morrisson TE, Whitmore AC, Shabman RS, Lidbury BA, Mahalingam S, Heise MT: Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol. 2006, 80: 737-49. 10.1128/JVI.80.2.737-749.2006.View ArticleGoogle Scholar
- Lidbury BA, Rulli NE, Suhrbier A, Smith PN, McColl SR, Cunningham AL, Tarkowski A, van Rooijen N, Fraser RJ, Mahalingam S: Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus. J Infect Dis. 2008, 197: 1585-93. 10.1086/587841.View ArticlePubMedGoogle Scholar
- Grivard P, Le Roux K, Laurent P, Fianu A, Perrau J, Gigan J, Hoarau G, Grondin N, Staikowsky F, Favier F, Michault A: Molecular and serological diagnosis of Chikungunya virus infection. Pathol Biol (Paris). 2007, 55: 490-4.View ArticleGoogle Scholar
- Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A, Arvin-Berod C, Paganin F: Persistent arthralgia associated with Chikungunya virus: a study of 88 adults patients on Reunion Island. Clin Infect Dis. 2008, 47: 469-79. 10.1086/590003.View ArticlePubMedGoogle Scholar
- Khan MA, Matthieu A, Sorrentino R, Akkoc N: The pathogenetic role of HLA-B27 and its subtypes. Autoimmunity Rev. 2007, 6: 183-9. 10.1016/j.autrev.2006.11.003.View ArticleGoogle Scholar
- Cohen A, Schoenfeld Y: The viral autoimmunity relationship. Viral Immunol. 1995, 8: 1-9. 10.1089/vim.1995.8.1.View ArticlePubMedGoogle Scholar
- Schoenfeld Y: Common infections, idiotypic dysregulation, autoantibodies spread and induction of autoimmune diseases. J Autoimmun. 1996, 9: 235-9. 10.1006/jaut.1996.0029.View ArticleGoogle Scholar
- Fiorillo MT, Ruckert C, Huhsmeyer M, Sorrentino R, Saenger W, Ziegler A, Uchanska-Ziegler B: Allelle-dependant similarity between viral and self-peptide presentation by HLA-B27 subtypes. J Biol Chem. 2005, 280: 2962-71. 10.1074/jbc.M410807200.View ArticlePubMedGoogle Scholar
- Rot A, von Andrian UH: Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004, 22: 891-928. 10.1146/annurev.immunol.22.012703.104543.View ArticlePubMedGoogle Scholar
- Dinarello CA: Biologic basis for interleukin-1 in disease. Blood. 1996, 87: 2095-147.PubMedGoogle Scholar
- Takeuchi O, Akira S: Recognition of viruses by innate immunity. Immunol Rev. 2007, 220: 214-24. 10.1111/j.1600-065X.2007.00562.x.View ArticlePubMedGoogle Scholar
- Honda K, Takaoda A, Taniguchi T: Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006, 25: 349-60. 10.1016/j.immuni.2006.08.009.View ArticlePubMedGoogle Scholar
- Stetson DB, Medzhitov R: Type I interferons in host defense. Immunity. 2006, 25: 373-81. 10.1016/j.immuni.2006.08.007.View ArticlePubMedGoogle Scholar
- Lin SC, Shyur SD, Ma YC, Huang LH, Lee WI: Hyper-IgM1 syndrome with interstitial pneumonia and diarrhaea caused by coxsackie virus B4 in a 3-month-old infant. Ann Allergy Asthma Immunol. 2005, 95: 93-7.View ArticlePubMedGoogle Scholar
- Qiao X, He B, Shin A, Knowles DN, Chadburn A, Cerruti A: Human immunodeficiency virus 1 Nef suppresses CD40-dependant immunoglobulin class switching in bystander B-cells. Nat Immunol. 2006, 7: 302-10. 10.1038/ni1302.View ArticlePubMedGoogle Scholar
- Sitati E, McCandless EE, Klein RS, Diamond MS: CD40-ligand interactions promote trafficking of CD8+ T-cells into the brain and protection against West Nile encephalitis. J Virol. 2007, 81: 9801-11. 10.1128/JVI.00941-07.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/9/200/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.